The Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for treating patients with Hodgkin lymphoma who have already had a stem cell transplant or are not eligible for one. The drug was also approved for patients with systemic anaplastic large-cell lymphoma (ALCL), who have not improved with at least one previous therapy. Adcetris is a newer type of drug known as an antibody-drug conjugate: a manmade antibody that targets a molecule found on some lymphoma cells, combined with a chemotherapy drug. The antibody acts as a sort of homing signal to bring the chemo drug directly to the lymphoma cells.
n a 2010 trial34% of patients with refractory Hodgkin Lymphoma achieved complete remission and another 40% had partial remission.Tumor reductions were achieved in 94% of patients. In ALCL, 87% of patients had tumors shrink at least 50% and 97% of patients had some tumor shrinkage. There are no published studies of this drug in and for first line therapy.
NCT00848926 – A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Cytotoxic Agents | ADC Review / Journal of Antibody-drug Conjugates, May 23, 2013 
Prescribing Information,(US)/Adcetris (brentuximab vedotin) for Injection (2013)